Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
about
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsFludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialThe long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative GrouDonor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature.Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allAllogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrRecipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantationNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioComorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells.Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesAssociation of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipientsHigh Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamideSecond autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.A disease risk index for patients undergoing allogeneic stem cell transplantation.(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell TransplantationEfficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioningComparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationAllogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantationInterleukin-2 and regulatory T cells in graft-versus-host disease.
P2860
Q26770716-9D268146-AB51-47D0-86FB-CAA8364BEB14Q26849243-CB2B55BD-56AE-4DC6-B184-ECAD72111404Q30543777-0F4A75EC-095C-4B22-8839-3E7E8450CA38Q31143348-0210CC1A-394A-483E-BE34-13560842CFE6Q33394527-EF17F8FF-AE73-46B5-880B-3BA0EA4B0242Q33560410-3410C7A0-9326-4BE9-9A57-E4C96BDD6561Q33653406-A732D15C-76B5-4467-B8ED-08A97E44D719Q33771667-77B43473-B5B2-4012-B7C2-A9AEA0C410E2Q33813439-729A6F4D-FEFD-49BB-8CC5-08AA65517C33Q33905541-CFFD4A14-5A89-43D2-8347-A548F2615685Q33917170-D96CA008-C25B-40F7-989B-72DA63B2A5A8Q33958019-8B5AB7AA-7EBE-452A-8AB7-95334F6BDB6AQ33990856-313CDDC4-33DA-4093-8C61-8034F877D896Q34044024-BFAD4AEF-51F6-4FB2-A65F-8F96F227D3B9Q34175259-D9E26BB7-9422-46F0-9958-9886B70D2776Q34202277-DA7A8178-5A2B-4D9B-9178-FD8716D5B0DBQ34260505-52B1E3EB-0608-478F-8143-BA27E1047AFDQ34272554-CFBF7CC7-61BC-40B8-AE91-5240C5EBEF0CQ34577694-22AB1F0F-9FE0-46F4-BD14-1E34269AB54CQ34749088-9CEC787C-4275-4086-B876-796F37EB8F2DQ35095722-87F3732C-67A1-43DB-9F8D-CB88350829DBQ35554703-B9104F0C-E353-487D-B747-B5010B2BAE48Q35811940-E36ACC4C-C94D-4B94-BF31-4E57226B175AQ35847466-EC890636-A5A4-4982-B728-6D7887A8D25BQ35877266-E5AFBCCE-D5B3-4B9B-B453-17424CA18233Q35964878-B47CFA97-16EF-476B-AEF2-5C7F8A1457BBQ36028751-C6150E0D-A508-458A-9E14-85EFAD4B8F00Q36117735-5B225301-046E-4404-8376-3E15E9007B1FQ36141944-465F8442-4AB1-438A-B4D8-72389E478FBCQ36229571-2B3F0381-8898-47CC-BA51-29651DEDED10Q36306393-9CC4EE6E-BEA6-4CD8-86E4-65E54387762EQ36319726-64EF752D-ACE4-4F74-B587-85011C187F9EQ36320260-972E7315-0B39-4CD7-B844-BFFB3E54ECB2Q36761521-30AE4E97-C5C3-4328-8C91-BAADE8578F53Q36763834-1466A9F4-5F69-4EAD-B43D-24C21B9504CCQ36774150-785052B8-29CE-4344-B360-FBAC64B39D2CQ36984852-FA7B4D8F-FA46-47DD-975D-889B48F658BAQ36994811-A5164E49-4B15-4185-9686-F2EAF5FE8CB5Q37038889-338BCE10-52C5-4223-A916-73B1370DAAF9Q37055805-9E2F6363-D3C7-4F18-935D-E0F3A9110D36
P2860
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Relapse risk in patients with ...... nonmyeloablative conditioning.
@ast
Relapse risk in patients with ...... nonmyeloablative conditioning.
@en
type
label
Relapse risk in patients with ...... nonmyeloablative conditioning.
@ast
Relapse risk in patients with ...... nonmyeloablative conditioning.
@en
prefLabel
Relapse risk in patients with ...... nonmyeloablative conditioning.
@ast
Relapse risk in patients with ...... nonmyeloablative conditioning.
@en
P2093
P2860
P50
P1433
P1476
Relapse risk in patients with ...... nonmyeloablative conditioning.
@en
P2093
Amelia Langston
Benedetto Bruno
Christoph Kahl
Dietger Niederwieser
Edward Agura
Elliot Epner
Finn Bo Petersen
James C Wade
Jose F Leis
Karl G Blume
P2860
P304
P356
10.1182/BLOOD-2007-03-078592
P407
P577
2007-06-26T00:00:00Z